Skip to main content

What type of drug is Bavencio?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Feb 12, 2024.

Official answer

by Drugs.com

Bavencio (avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody.

Bavencio targets the PD-L1 receptors, which are protein receptors on cell surfaces. When Bavencio blocks PD-L1, it 'turns on' the ability of cancer-fighting cells such as T-cells to attack and kill tumors.

Learn More: Checkpoint Inhibitors & Advanced Cancers: A Health Care Professional's Guide

Bavencio is used for the treatment of:

References
  • Bavencio (avelumab) [product information]. EMD Serono, Inc.
    Rockland, MA. Accessed Feb. 20, 2021 at https://www.emdserono.com/us-en/pi/bavencio-pi.pdf

Read next

Who makes Bavencio and where is it made?

Bavencio is made by EMD Serono, Inc., a pharmaceutical company located in Rockland, Massachusetts, USA. You can contact EMD Serono by calling +1-800-283-8088 or contact them online. Continue reading

How long does it take for Keytruda to work?

The time it takes for Keytruda to work can vary based on the type and stage of cancer. Typically, a response to treatment becomes apparent within 2-4 months of starting Keytruda. This timeframe is referred to as "time to response," which measures when a patient's cancer begins to show signs of responding to the treatment. You can find the specific "time to response" data from clinical trials in the table below. Continue reading

What is the success rate of Keytruda?

In general, PD-1 immune checkpoint inhibitors like Keytruda have been shown to significantly prolong overall survival (OS) in some patients with various cancer types, but Keytruda does not always work for everyone. Continue reading

Related medical questions

Drug information

Related support groups